Abano forecasts FY loss of $1.3M-$1.9M on sale of Aotea stake, Orthotics

Thu, 23 Apr 2015

By Jonathan Underhill April 24 (BusinessDesk) - Abano Healthcare expects to report a small full-year loss after the specialist medical investment firm agreed to sell its stake in Aotea Pathology and following the sale of its orthotics unit in January, which resulted in impairments on both businesses. The net loss is expected to be $1.3 million to $1.9 million in the year ending May 31, the Auckland-based company said in a statement. Excluding impairments and loss on sale, annual profit is forecast at $7.2 million to $7.8 million, up from...
Economy
BRIAN GAYNOR: Aluminium smelter reaches use by date
Brian Gaynor | Sat, 11 Jul 2020

The negative market reaction to Rio Tinto’s announcement that it was winding down the Tiwai Point aluminium smelter was overdone, particularly for investors with long-term perspectives. The smelter...

Markets
MARKET CLOSE: NZ shares fall as energy sector sell-off continues
Dan Brunskill | Fri, 10 Jul 2020

New Zealand shares fell as energy stocks declined for a second day following the announcement Rio Tinto’s New Zealand aluminium smelter will close. Chorus led the market lower on the risk of more r...

Finance
Metlifecare and EQT enter new $6 per share takeover agreement
Jenny Ruth | Fri, 10 Jul 2020

Metlifecare said it has entered into a new scheme of arrangement with Swedish company EQT to buy all its shares for $6 each, a dollar less than the earlier deal EQT had repudiated, but only four of th...

The role of private equity in the wake of COVID-19

As local covid-19 restrictions ease, a new business cycle is beginning in New Zealand.

Sponsored: What’s next for the future of the office?

Think everyone is going to keep working from home? No so fast, says Milford Asset Management.